Literature DB >> 7936057

Cortical glucose metabolism in Parkinson's disease without dementia.

J L Eberling1, B C Richardson, B R Reed, N Wolfe, W J Jagust.   

Abstract

There have been several reports of decreased regional cerebral metabolic rates for glucose (rCMRglc) in Parkinson's disease (PD), although others find no differences between PD patients and controls. Differences in the cognitive status of the PD patients may account for some of these inconsistencies. We report the results of a PET study using 18F-fluorodeoxyglucose (FDG) to measure rCMRglc in eight nondemented PD patients, six of whom were receiving dopaminergic medications, and eight age-matched control subjects. We scanned one tomographic level through the temporal lobes that included both temporal neocortex and mesial temporal cortex, and one tomographic level through the basal ganglia that included frontal and parietal cortex. Previously determined rate constants and an operational equation were used to determine rCMRglc. On average, rCMRglc values were 23% below control values for all regions studied, with the greatest differences in posterior brain regions (visual association cortex, primary visual cortex, and parietal cortex) and thalamus. These results indicate that PD patients may show neocortical hypometabolism, especially in posterior brain regions, in the absence of any demonstrable cognitive deficits.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936057     DOI: 10.1016/0197-4580(94)90028-0

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  26 in total

Review 1.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

2.  Glucose Metabolism and AMPK Signaling Regulate Dopaminergic Cell Death Induced by Gene (α-Synuclein)-Environment (Paraquat) Interactions.

Authors:  Annadurai Anandhan; Shulei Lei; Roman Levytskyy; Aglaia Pappa; Mihalis I Panayiotidis; Ronald L Cerny; Oleh Khalimonchuk; Robert Powers; Rodrigo Franco
Journal:  Mol Neurobiol       Date:  2016-06-20       Impact factor: 5.590

3.  Functional connectome assessed using graph theory in drug-naive Parkinson's disease.

Authors:  Chun Yan Luo; Xiao Yan Guo; Wei Song; Qin Chen; Bei Cao; Jing Yang; Qi Yong Gong; Hui-Fang Shang
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

4.  [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor.

Authors:  S Breit; M Reimold; G Reischl; T Klockgether; U Wüllner
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

5.  Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease.

Authors:  Alireza Kashani; Catalina Betancur; Bruno Giros; Etienne Hirsch; Salah El Mestikawy
Journal:  Neurobiol Aging       Date:  2006-03-24       Impact factor: 4.673

6.  Hippocampal responsiveness to 17β-estradiol and equol after long-term ovariectomy: implication for a therapeutic window of opportunity.

Authors:  Ryan T Hamilton; Jamaica R Rettberg; Zisu Mao; Jimmy To; Liqin Zhao; Susan E Appt; Thomas C Register; Jay R Kaplan; Roberta Diaz Brinton
Journal:  Brain Res       Date:  2011-01-15       Impact factor: 3.252

7.  Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinson's disease.

Authors:  Kazuya Kawabata; Hirohisa Watanabe; Kazuhiro Hara; Epifanio Bagarinao; Noritaka Yoneyama; Aya Ogura; Kazunori Imai; Michihito Masuda; Takamasa Yokoi; Reiko Ohdake; Yasuhiro Tanaka; Takashi Tsuboi; Tomohiko Nakamura; Masaaki Hirayama; Mizuki Ito; Naoki Atsuta; Satoshi Maesawa; Shinji Naganawa; Masahisa Katsuno; Gen Sobue
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

8.  Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing.

Authors:  Y Abe; T Kachi; T Kato; Y Arahata; T Yamada; Y Washimi; K Iwai; K Ito; N Yanagisawa; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

9.  Upregulation of a small vault RNA (svtRNA2-1a) is an early event in Parkinson disease and induces neuronal dysfunction.

Authors:  Elena Miñones-Moyano; Marc R Friedländer; Joan Pallares; Birgit Kagerbauer; Sílvia Porta; Georgia Escaramís; Isidre Ferrer; Xavier Estivill; Eulàlia Martí
Journal:  RNA Biol       Date:  2013-05-01       Impact factor: 4.652

10.  Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia.

Authors:  Paul Edison; Imtiaz Ahmed; Zhen Fan; Rainer Hinz; Giorgio Gelosa; K Ray Chaudhuri; Zuzana Walker; Federico E Turkheimer; David J Brooks
Journal:  Neuropsychopharmacology       Date:  2012-12-06       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.